Related Experiment Video
Updated: Dec 21, 2025
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
Pazopanib for metastatic soft-tissue sarcoma: A multicenter retrospective study
Sinan Koca1, Mehmet Beşiroğlu2, Melike Özçelik3
1Department of Medical Oncology, Goztepe Training and Research Hospital, Istanbul Medeniyet University, Istanbul, Turkey.
Purpose:
Soft tissue sarcomas are associated with a poor prognosis and low chemotherapeutic efficiency. Pazopanib is an orally available multi-tyrosine kinase inhibitor that was explored in patients with non-adipocytic advanced soft tissue sarcomas. The aim of this retrospective study was to evaluate the real life data of single-agent pazopanib efficacy and safety for soft tissue sarcomas in the Turkish population.
Materials And Methods:
We evaluated a total of 103 patients (41 males, 62 females) who received pazopanib for advanced non-adipocytic soft tissue sarcomas diagnosis in eight centers of Turkey, retrospectively. The pazopanib dose was 800 mg once daily. Progression-free survival, overall survival, and adverse events were analyzed.
Results:
The median age was 50 years (range, 38-58). Majority of the patients had leimyosarcoma (41%). Median progression-free survival was 4.3 months, and the median overall survival was 10.1 months. The main common toxicities were fatigue, anorexia, weight loss, nausea, hypertension, and grade ≥3 toxicities were fatigue, anorexia, weight loss, and liver disorder.
Conclusion:
Pazopanib is an efficient and tolerable agent and is well tolerated in good performance status patients with relapsed, advanced non-adipocytic soft tissue sarcomas.
Insights
Pazopanib showed efficacy in treating advanced soft tissue sarcomas in Turkey, with manageable side effects. This study evaluated real-world data on pazopanib for soft tissue sarcoma patients.
Area of Science:
- Oncology
- Pharmacology
Background:
- Soft tissue sarcomas (STS) often present with poor prognosis and limited response to chemotherapy.
- Pazopanib, a multi-tyrosine kinase inhibitor, offers a potential therapeutic option for advanced STS.
Purpose of the Study:
- To assess the real-world efficacy and safety of single-agent pazopanib in Turkish patients with advanced non-adipocytic soft tissue sarcomas.
- To provide data on pazopanib's performance in a specific patient population.
Main Methods:
- A retrospective analysis of 103 patients with advanced non-adipocytic STS treated with pazopanib (800 mg daily) across eight Turkish centers.
- Evaluation of progression-free survival (PFS), overall survival (OS), and adverse events.
Main Results:
- The median PFS was 4.3 months and the median OS was 10.1 months.
- Common toxicities included fatigue, anorexia, weight loss, and nausea. Grade ≥3 toxicities involved fatigue, anorexia, weight loss, and liver disorders.
- Leimyosarcoma was the most frequent subtype (41%).
Conclusions:
- Pazopanib is an effective and tolerable treatment for patients with relapsed, advanced non-adipocytic soft tissue sarcomas.
- Patients with good performance status tolerated pazopanib well.
